Page last updated: 2024-09-04

bazedoxifene and Bone Loss, Perimenopausal

bazedoxifene has been researched along with Bone Loss, Perimenopausal in 88 studies

Research

Studies (88)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	13 (14.77)	29.6817
2010's	70 (79.55)	24.3611
2020's	5 (5.68)	2.80

Authors

Authors	Studies
Adhikari, N; Bhattacharjee, M; Gupta, D; Pamnani, S; Panda, A; Rizvi, Z; Shehzad, S; Sijwali, PS; Sudhakar, R	1
Emoto, M; Imanishi, Y; Inaba, M; Kurajoh, M; Masaki, H; Miki, T; Mori, K; Nagata, Y; Naka, H	1
Choi, D; Kim, BM; Kim, SE; Lee, DY	1
Cho, SK; Choi, YY; Kim, H; Lee, J; Lee, S; Nam, E; Sung, YK	1
Hara, T; Hijikata, Y; Matsubara, Y; Watanabe, N	1
Arias, L; Bueno, JAH; Komm, BS; Williams, R; Yu, CR	1
Lu, H; Luo, Q; Peng, L	1
Boucher, M; Morgenstern, D; Pickar, JH	1
Conner, EA; Pinkerton, JV	1
Anastasilakis, AD; Makras, P; Yavropoulou, MP	1
Chines, A; Kaufman, JM; Palacios, S; Silverman, S; Sutradhar, S	1
Gatti, D; Lello, S; Rossini, M; Sblendorio, I	1
Komm, BS; Mirkin, S; Pinkerton, JV	1
Komm, BS; Mirkin, S	1
Chines, AA; de Villiers, TJ; Hines, T; Levine, AB; Mirkin, S; Nardone, Fde C; Palacios, S; Williams, R	1
Adami, S; Chines, AA; Levine, AB; Palacios, S; Rizzoli, R; Sutradhar, S	1
Kanis, JA; Kim, K; Luo, X; Sutradhar, S; Svedbom, A	1
Chandran, AB; Komm, BS; Mirkin, S; Ryan, KA	1
Pinkerton, JV; Thomas, S	1
Ferrari, S; Hadji, P; Reginster, JY	1
Lewiecki, EM; Sharifi, M	1
Chouinard, L; Jolette, J; Komm, BS; Smith, SY	1
Chines, AA; Constantine, GD; Gorai, I; Itabashi, A; Miki, T; Mizunuma, H; Ochi, H; Ohta, H; Sato, H; Sugimoto, T; Takada, M; Yoh, K	2
Bushmakin, AG; Ellis, AG; Jansen, JP; Luo, X; Mirkin, S; Reginster, JY; Sutradhar, S; Williams, R	1
Abraham, L; Komm, BS; Messig, M; Mirkin, S; Pinkerton, JV; Ryan, KA	1
Jenkins, SN; Komm, BS; Mirkin, S	1
Cappelleri, JC; Chines, A; Ellis, AG; Jansen, JP; Luo, X; Reginster, JY; Sutradhar, S	1
Ohta, H; Solanki, J	1
Brown, JP; Chines, AA; De Cicco Nardone, F; de Villiers, TJ; Goemaere, S; Hines, TL; Levine, AB; Mirkin, S; Palacios, S; Silverman, SL; Williams, R	1
Mejía Ríos, A; Palacios, S	1
Beck, TJ; Chines, AA; Fuerst, T; Gaither, KW; Hines, T; Levine, AB; Mirkin, S; Sutradhar, S; Williams, R; Yu, CR	1
Komm, B; Mirkin, S; Santen, RJ; Smith, CL	1
Lovre, D; Mauvais-Jarvis, F; Xu, B	1
Arakawa, S; Kida, Y; Marumo, K; Nishizawa, T; Okabe, H; Saito, M; Seki, A	1
Andersson, A; Bernardi, AI; Carlsten, H; Islander, U; Nurkkala-Karlsson, M; Ohlsson, C; Stubelius, A	1
Chaki, O	2
Hauck, F; Johnson, K	1
Archer, DF; Kagan, R; Komm, BS; Mirkin, S; Pan, K; Pickar, JH; Pinkerton, JV; Thompson, JR	1
Arias, L; Komm, BS; Mirkin, S; Palacios, S; Pan, K; Williams, R	1
Gallagher, JC; Kendler, DL; Komm, BS; Mirkin, S; Palacios, S; Pan, K; Ryan, KA; Yu, CR	1
Hadji, P; Komm, BS; Mirkin, S; Ryan, KA; Yu, CR	1
Gillespie, JA; Parish, SJ	1
Mitwally, MF	1
Bobula, J; Lips, P; van Schoor, NM; Yu, H	1
Johansson, H; Kanis, JA; McCloskey, EV; Oden, A	1
Chu, EY; Kung, AW; Xu, L	1
Constantine, G; Gallagher, JC; Kagan, R; Lindsay, R; Pickar, JH	1
Chines, AA; Komm, BS	2
Lewiecki, EM	2
de Villiers, TJ	1
Palacios, S	2
Borgström, F; Johansson, H; Kanis, JA; Kleman, M; McCloskey, E; Odén, A; Ström, O	2
Brown, JP; Chines, AA; Codreanu, C; de Villiers, TJ; Kelepouris, N; Levine, AB; Lips, P; Palacios, S; Sawicki, AZ	1
Adachi, JD; Brown, JP; Chesnut, CH; Chines, AA; Christiansen, C; Constantine, GD; Fernandes, CE; Kung, AW; Levine, AB; Palacios, S	1
Archer, DF	2
Schmidt, C	1
Lindsay, R	1
Pinkerton, JV; Stovall, DW	1
Ohta, H	2
Bachmann, G; Constantine, GD; Crosby, U; Feldman, RA; Ronkin, S	1
Lello, S	1
Genant, HK	1
Kawate, H; Takayanagi, R	1
Adachi, JD; Chines, AA; Constantine, GD; Felsenberg, D; Kendler, DL; Kung, AW; Mairon, N; Silverman, SL; Teglbjærg, CS	1
Harada, T; Ochi, H; Ochi, Y	1
Pinkerton, JV; Stovall, DW; Tanner-Kurtz, K	1
Schneider, DL	1
Duggan, ST; McKeage, K	1
Duggan, ST; Keating, GM; Lyseng-Williamson, KA; McKeage, K	1
Tuppurainen, M	1
Hadji, P	1
Bruyère, O; Chines, A; Detilleux, J; Reginster, JY	1
Chines, AA; Komm, BS; Mirkin, S; Pan, K	1
Ben Sedrine, W; Hiligsmann, M; Reginster, JY	1
Rizzoli, R; Uelbelhart, B	1
Calaf Alsina, J; Coronado Martín, PJ	1
Gruber, C; Gruber, D	1
Kelley, KW; Stump, AL; Wensel, TM	1
Biskobing, DM	1

Reviews

47 review(s) available for bazedoxifene and Bone Loss, Perimenopausal

Article	Year
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. The Cochrane database of systematic reviews, 2021, Jul-07, Volume: 7 Topics: Antibodies, Monoclonal; Bias; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Femur Neck; Fractures, Spontaneous; Hip; Humans; Indoles; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spinal Fractures; Teriparatide; Thiophenes; Watchful Waiting	2021
Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: A systematic review and meta-analysis. Medicine, 2017, Volume: 96, Issue:49 Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; Spine; Time Factors; Treatment Outcome	2017
Tissue selective estrogen complex (TSEC): a review. Menopause (New York, N.Y.), 2018, Volume: 25, Issue:9 Topics: Bone Density; Breast Neoplasms; Drug Synergism; Drug Therapy, Combination; Endometrium; Estrogens; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Humans; Indoles; Menopause; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2018
Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Climacteric : the journal of the International Menopause Society, 2019, Volume: 22, Issue:2 Topics: Adult; Aged; Atrophy; Breast Neoplasms; Estrogens, Conjugated (USP); Female; Female Urogenital Diseases; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina	2019
Bazedoxifene for the treatment of osteoporosis. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:10 Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures	2019
Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:7 Topics: Aged; Drug Evaluation; Estrogens, Conjugated (USP); Female; Humans; Indoles; Menopause; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2013
Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model. Climacteric : the journal of the International Menopause Society, 2013, Volume: 16, Issue:6 Topics: Animals; Atrophy; Estrogens, Conjugated (USP); Female; Gene Expression; Hot Flashes; Humans; Indoles; Lipid Metabolism; Osteoporosis, Postmenopausal; Quality of Life; Selective Estrogen Receptor Modulators; Sleep; Vagina; Venous Thromboembolism; Vulva	2013
Tissue-selective estrogen complexes for postmenopausal women. Maturitas, 2013, Volume: 76, Issue:3 Topics: Breast; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Sleep; Uterus; Vaginal Diseases	2013
Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms. Maturitas, 2014, Volume: 77, Issue:1 Topics: Estrogens; Estrogens, Conjugated (USP); Hot Flashes; Humans; Indoles; Menopause; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2014
Use of SERMs for treatment in postmenopausal women. The Journal of steroid biochemistry and molecular biology, 2014, Volume: 142 Topics: Breast Neoplasms; Clinical Trials as Topic; Dyspareunia; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Toremifene	2014
Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene. Current medical research and opinion, 2014, Volume: 30, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal	2014
Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert review of clinical pharmacology, 2014, Volume: 7, Issue:3 Topics: Bone Density; Cell Line, Tumor; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Indoles; Menopause; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Treatment Outcome	2014
Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Current medical research and opinion, 2014, Volume: 30, Issue:8 Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Regression Analysis; Spinal Fractures; Treatment Outcome	2014
Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss. Steroids, 2014, Volume: 90 Topics: Estrogens; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis, Postmenopausal	2014
Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2014, Volume: 17, Issue:4 Topics: Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal	2014
Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2015, Volume: 26, Issue:3 Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2015
Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women. Drugs of today (Barcelona, Spain : 1998), 2015, Volume: 51, Issue:2 Topics: Bone Density; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Indoles; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2015
Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes. Breast cancer research : BCR, 2014, Jun-18, Volume: 16, Issue:3 Topics: Bone Density; Breast; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2014
Effect of selective estrogen receptor modulators on metabolic homeostasis. Biochimie, 2016, Volume: 124 Topics: Animals; Breast; Breast Neoplasms; Diabetes Mellitus, Type 2; Disease Models, Animal; Estrogens; Female; Humans; Indoles; Metabolic Syndrome; Osteoporosis, Postmenopausal; Receptors, Estrogen; Uterus	2016
Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms. American family physician, 2016, Feb-15, Volume: 93, Issue:4 Topics: Bone Density Conservation Agents; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Indoles; Menopause; Osteoporosis, Postmenopausal	2016
Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:10 Topics: Bone Density; Bone Density Conservation Agents; Bone Remodeling; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic	2016
The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms. Postgraduate medicine, 2017, Volume: 129, Issue:3 Topics: Age Factors; Bone Remodeling; Breast Neoplasms; Cardiovascular Diseases; Drug Administration Routes; Drug Combinations; Endometrial Hyperplasia; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Osteoporosis, Postmenopausal; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Sleep Wake Disorders; Time Factors; Vagina	2017
Bazedoxifene: a selective estrogen-receptor modulator. Women's health (London, England), 2008, Volume: 4, Issue:4 Topics: Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Female; Hot Flashes; Humans; Indoles; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Women's Health	2008
Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:8 Topics: Clinical Trials as Topic; Humans; Indoles; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2009
Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Drugs of today (Barcelona, Spain : 1998), 2009, Volume: 45, Issue:7 Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2009
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. Journal of women's health (2002), 2009, Volume: 18, Issue:10 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Drug Therapy, Combination; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Vitamin D; Women's Health	2009
Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. Climacteric : the journal of the International Menopause Society, 2010, Volume: 13, Issue:3 Topics: Clinical Trials, Phase III as Topic; Endometrium; Female; Fractures, Bone; Humans; Indoles; Lipids; Mammography; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Ultrasonography; Venous Thromboembolism	2010
Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Current medical research and opinion, 2010, Volume: 26, Issue:7 Topics: Bone Density Conservation Agents; Female; Humans; Indoles; Models, Biological; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Treatment Outcome	2010
Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms. Drugs & aging, 2010, Jul-01, Volume: 27, Issue:7 Topics: Aged; Animals; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2010
Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE). Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:2 Topics: Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Collagen Type I; Endometrium; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Osteoporosis, Postmenopausal; Peptides; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Treatment Outcome; Vaginal Diseases	2011
Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:12 Topics: Animals; Clinical Trials as Topic; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis, Postmenopausal; Postmenopause; Selective Estrogen Receptor Modulators; Treatment Outcome	2010
[Bazedoxifene as a new-generation SERM]. Clinical calcium, 2011, Volume: 21, Issue:1 Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2011
Bazedoxifene acetate for the management of postmenopausal osteoporosis. Drugs of today (Barcelona, Spain : 1998), 2011, Volume: 47, Issue:3 Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2011
[Selective estrogen receptor modulators: focus on bazedoxifene]. Minerva ginecologica, 2011, Volume: 63, Issue:3 Topics: Female; Humans; Indoles; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2011
Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clinical interventions in aging, 2011, Volume: 6 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Outcome Assessment, Health Care	2011
[Pharmacology profile and clinical findings of Viviant(®) (bazedoxifene acetate) tablet ]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2011, Volume: 138, Issue:2 Topics: Animals; Bone Density; Female; Haplorhini; Humans; Indoles; Osteoporosis, Postmenopausal; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tablets	2011
Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis. Drugs, 2011, Nov-12, Volume: 71, Issue:16 Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Treatment Outcome	2011
An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. Maturitas, 2012, Volume: 71, Issue:3 Topics: Bone Density Conservation Agents; Breast; Endometrium; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes	2012
HT and SERMs in the long-term management of osteoporosis. Minerva ginecologica, 2012, Volume: 64, Issue:3 Topics: Bone Density Conservation Agents; Female; Hormone Replacement Therapy; Humans; Indoles; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2012
The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes	2012
[Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action]. Medicina clinica, 2013, Mar-16, Volume: 140, Issue:6 Topics: Adenocarcinoma; Animals; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Multicenter Studies as Topic; Organ Specificity; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Thromboembolism	2013
Bazedoxifene (Wyeth). Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:10 Topics: Animals; Clinical Trials as Topic; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Treatment Outcome	2004
[Therapeutic agents for disorders of bone and calcium metabolism: Bazedoxifene]. Clinical calcium, 2007, Volume: 17, Issue:1 Topics: Animals; Breast Neoplasms; Cholesterol; Female; Fractures, Spontaneous; Hot Flashes; Humans; Indoles; Osteoporosis, Postmenopausal; Rats; Selective Estrogen Receptor Modulators; Uterus	2007
Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:5 Topics: Animals; Bone Density Conservation Agents; Clinical Trials as Topic; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2007
Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Expert opinion on investigational drugs, 2007, Volume: 16, Issue:10 Topics: Animals; Bone Density; Clinical Trials as Topic; Drug Therapy, Combination; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Indoles; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2007
Update on bazedoxifene: a novel selective estrogen receptor modulator. Clinical interventions in aging, 2007, Volume: 2, Issue:3 Topics: Animals; Bone Density Conservation Agents; Estrogens; Female; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterus	2007
[Status of novel bone-targeting SERMs in development]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Animals; Bone and Bones; Bone Density; Clinical Trials as Topic; Drug Design; Humans; Indoles; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Rats; Receptors, Estrogen; Research; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thiophenes	2007

Trials

22 trial(s) available for bazedoxifene and Bone Loss, Perimenopausal

Article	Year
Bazedoxifene improves renal function and increases renal phosphate excretion in patients with postmenopausal osteoporosis. Journal of bone and mineral metabolism, 2020, Volume: 38, Issue:3 Topics: Aged; Bone Density; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Homeostasis; Humans; Indoles; Kidney; Linear Models; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphates	2020
Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients. Arthritis research & therapy, 2021, 07-02, Volume: 23, Issue:1 Topics: Arthritis, Rheumatoid; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Female; Glucocorticoids; Humans; Indoles; Lumbar Vertebrae; Osteoporosis, Postmenopausal	2021
Efficacy and safety of bazedoxifene in postmenopausal Latino women with osteoporosis. Menopause (New York, N.Y.), 2017, Volume: 24, Issue:9 Topics: Bone Density; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Fractures, Bone; Humans; Indoles; Latin America; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Placebos; Postmenopause; Selective Estrogen Receptor Modulators; Spinal Fractures	2017
An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:10 Topics: Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Kaplan-Meier Estimate; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Assessment; Spinal Fractures; Treatment Outcome	2013
Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas, 2013, Volume: 76, Issue:1 Topics: Aged; Bone Density Conservation Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Humans; Incidence; Indoles; Middle Aged; Neoplasms, Glandular and Epithelial; Osteoporosis, Postmenopausal; Ovarian Neoplasms; Postmenopause; Selective Estrogen Receptor Modulators; Spinal Fractures; Ultrasonography; Vaginitis	2013
The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status. Climacteric : the journal of the International Menopause Society, 2014, Volume: 17, Issue:3 Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Double-Blind Method; Female; Fractures, Bone; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Postmenopause	2014
Bridging analysis of the efficacy and safety of bazedoxifene in Japanese and global populations of postmenopausal women with osteoporosis. Journal of bone and mineral metabolism, 2015, Volume: 33, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Cohort Studies; Double-Blind Method; Female; Fracture Healing; Fractures, Bone; Humans; Indoles; Japan; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Safety; Postmenopause	2015
Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Maturitas, 2014, Volume: 78, Issue:3 Topics: Double-Blind Method; Estrogens; Estrogens, Conjugated (USP); Female; Genital Diseases, Female; Hot Flashes; Humans; Indoles; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Quality of Life; Selective Estrogen Receptor Modulators; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Vagina; Vaginal Diseases; Vulva; Vulvar Diseases	2014
A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:8 Topics: Aged; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Indoles; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Postmenopause; Time; Treatment Outcome	2015
The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis. Bone, 2015, Volume: 77 Topics: Absorptiometry, Photon; Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cohort Studies; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Placebos	2015
Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials. Journal of women's health (2002), 2016, Volume: 25, Issue:5 Topics: Bone Density; Bone Density Conservation Agents; Breast; Drug Therapy, Combination; Endometrial Hyperplasia; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Incidence; Indoles; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Selective Estrogen Receptor Modulators; Uterine Hemorrhage	2016
Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trial. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:7 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Humans; Indoles; Mexico; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Treatment Outcome	2016
CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis. Climacteric : the journal of the International Menopause Society, 2016, Volume: 19, Issue:5 Topics: Aged; Bone Density; Bone Remodeling; Collagen Type I; Double-Blind Method; Estrogens; Estrogens, Conjugated (USP); Europe; Female; Hot Flashes; Humans; Indoles; Menopause; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Quality of Life; Selective Estrogen Receptor Modulators; Treatment Outcome; United States; Vasomotor System	2016
Cross-geographic region differences in quality of life in women with and without vertebral fracture. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:10 Topics: Aged; Body Mass Index; Bone Density Conservation Agents; Epidemiologic Methods; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Psychometrics; Quality of Life; Raloxifene Hydrochloride; Spinal Fractures	2009
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone, 2009, Volume: 44, Issue:6 Topics: Aged; Algorithms; Bone Density Conservation Agents; Double-Blind Method; Female; Fractures, Bone; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Risk Factors; Spinal Fractures	2009
Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertility and sterility, 2009, Volume: 92, Issue:3 Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Collagen Type I; Dose-Response Relationship, Drug; Double-Blind Method; Estrogens; Estrogens, Conjugated (USP); Female; Hip Joint; Humans; Indoles; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2009
Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:2 Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Hot Flashes; Humans; Indoles; Middle Aged; Muscle Cramp; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Treatment Outcome; Venous Thrombosis	2011
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC musculoskeletal disorders, 2010, Jun-22, Volume: 11 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2010
Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2011, Volume: 26, Issue:3 Topics: Asian People; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Demography; Female; Humans; Incidence; Indoles; Japan; Lipid Metabolism; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures	2011
Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial. Menopause (New York, N.Y.), 2011, Volume: 18, Issue:5 Topics: Bone and Bones; Bone Density Conservation Agents; Female; Hot Flashes; Humans; Indoles; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2011
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:1 Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Placebos; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2012
Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric : the journal of the International Menopause Society, 2013, Volume: 16, Issue:3 Topics: Adult; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Endometrial Hyperplasia; Estrogens, Conjugated (USP); Female; Humans; Indoles; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Postmenopause; Selective Estrogen Receptor Modulators	2013

Other Studies

19 other study(ies) available for bazedoxifene and Bone Loss, Perimenopausal

Article	Year
Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation. Microbiology spectrum, 2022, 06-29, Volume: 10, Issue:3 Topics: Animals; Antimalarials; Female; Heme; Hemeproteins; Hemoglobins; Humans; Indoles; Malaria; Malaria, Falciparum; Male; Mice; Neoplasms; Osteoporosis, Postmenopausal; Plasmodium falciparum; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2022
Effect of Tissue-Selective Estrogen Complex on Hip Structural Geometry in Postmenopausal Women: A 12-Month Study. Frontiers in endocrinology, 2021, Volume: 12 Topics: Absorptiometry, Photon; Biomechanical Phenomena; Bone Density; Estrogens; Female; Femur; Femur Neck; Hip; Hip Fractures; Humans; Indoles; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Republic of Korea; Retrospective Studies	2021
Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:1 Topics: Aged; Algorithms; Bone Density Conservation Agents; Cost-Benefit Analysis; Decision Support Techniques; Dose-Response Relationship, Drug; Europe; Female; Health Care Costs; Health Services Research; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; Raloxifene Hydrochloride; Risk Assessment; Sensitivity and Specificity	2014
The effects of bazedoxifene in the ovariectomized aged cynomolgus monkey. Journal of bone and mineral metabolism, 2015, Volume: 33, Issue:2 Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Remodeling; Bone Resorption; Drug Evaluation, Preclinical; Female; Femur; Humans; Indoles; Lumbar Vertebrae; Macaca fascicularis; Osteoporosis, Postmenopausal; Ovariectomy; Selective Estrogen Receptor Modulators	2015
Conjugated estrogens/bazedoxifene (Duavee) for menopausal symptoms and prevention of osteoporosis. The Medical letter on drugs and therapeutics, 2014, Apr-28, Volume: 56, Issue:1441 Topics: Adult; Aged; Estrogens, Conjugated (USP); Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2014
Effects of 18-month treatment with bazedoxifene on enzymatic immature and mature cross-links and non-enzymatic advanced glycation end products, mineralization, and trabecular microarchitecture of vertebra in ovariectomized monkeys. Bone, 2015, Volume: 81 Topics: Animals; Arginine; Bone Density; Bone Density Conservation Agents; Collagen; Cross-Linking Reagents; Disease Models, Animal; Female; Glycation End Products, Advanced; Humans; Indoles; Lumbar Vertebrae; Lysine; Macaca fascicularis; Osteoporosis, Postmenopausal; Ovariectomy; Selective Estrogen Receptor Modulators; X-Ray Microtomography	2015
Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford, England), 2016, Volume: 55, Issue:3 Topics: Animals; Area Under Curve; Arthritis, Experimental; Biomarkers; Collagen; Disease Models, Animal; Female; Flow Cytometry; Humans; Indoles; Interleukin-6; Mice; Mice, Inbred DBA; Osteoarthritis; Osteoporosis, Postmenopausal; Ovariectomy; Pyrrolidines; Random Allocation; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome	2016
[Selective estrogen receptor modulators (SERMs)]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:10 Topics: Bone Density; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators	2015
FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone, 2010, Volume: 47, Issue:2 Topics: Aged; Aged, 80 and over; Algorithms; Bone Density Conservation Agents; Cost-Benefit Analysis; Fractures, Bone; Health Care Costs; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Risk Assessment; Sweden	2010
Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:3 Topics: Aged; Aged, 80 and over; Algorithms; Cost-Benefit Analysis; Europe; Female; Health Care Costs; Humans; Indoles; Markov Chains; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality-Adjusted Life Years; Risk Assessment; Selective Estrogen Receptor Modulators; Treatment Outcome	2011
Third-generation SERMs may face uphill battle. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration	2010
The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. Menopause (New York, N.Y.), 2011, Volume: 18, Issue:1 Topics: Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Female Urogenital Diseases; Humans; Indoles; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes	2011
Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. Menopause international, 2011, Volume: 17, Issue:2 Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Female; Humans; Indoles; Lipid Metabolism; Middle Aged; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Treatment Outcome	2011
Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms. Drugs, 2011, Sep-10, Volume: 71, Issue:13 Topics: Adult; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Vasomotor System	2011
Bone: in search of the perfect SERM--a 5-year study of bazedoxifene. Nature reviews. Endocrinology, 2011, Sep-20, Volume: 7, Issue:11 Topics: Animals; Bone Density Conservation Agents; Clinical Trials as Topic; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators	2011
Bazedoxifene: a guide to its use in postmenopausal osteoporosis. Drugs & aging, 2012, Apr-01, Volume: 29, Issue:4 Topics: Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal	2012
A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density. Statistical methods in medical research, 2016, Volume: 25, Issue:1 Topics: Bayes Theorem; Biostatistics; Bone Density; Bone Density Conservation Agents; Female; Humans; Indoles; Models, Statistical; Nonlinear Dynamics; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Treatment Outcome	2016
Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:4 Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Incidence; Indoles; Models, Economic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Placebos; Raloxifene Hydrochloride; Risk Factors; Treatment Outcome	2013
[Osteoporosis]. Revue medicale suisse, 2012, Jan-18, Volume: 8, Issue:324 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium; Denosumab; Diphosphonates; Female; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risk Assessment; Teriparatide; Treatment Outcome; Vitamin D	2012